- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 20.08. | OSR Holdings ändert Vereinbarungen mit White Lion Capital und beruft Hauptversammlung ein | 2 | Investing.com Deutsch | ||
| 20.08. | OSR Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.08. | OSR Holdings, Inc. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| OSR HOLDINGS Aktie jetzt für 0€ handeln | |||||
| 06.08. | OSR Holdings, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 31.07. | OSR Holdings informiert über Eigenkapitalfinanzierung und Aktienausgabe | 2 | Investing.com Deutsch | ||
| 31.07. | OSR Holdings updates on equity financing, shares issued under ELOC | 1 | Investing.com | ||
| 30.07. | OSR Holdings advances acquisition of Korean glucose monitoring firm | 1 | Investing.com | ||
| 30.07. | OSR Holdings Inc.: OSR Holdings Provides Strategic Update on Woori IO Term Sheet and Share Exchange Structure | 113 | PR Newswire | BELLEVUE, Wash. and SEOUL, South Korea, July 30, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company advancing biomedical and... ► Artikel lesen | |
| 25.07. | OSR Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 25.07. | Gambling Commission responds to OSR recommendations following GSGB review | 2 | iGaming Business | ||
| 24.07. | OSR Holdings signs term sheet to acquire noninvasive glucose tech firm | 1 | Investing.com | ||
| 24.07. | OSR Holdings enters term sheet to acquire Woori IO | 1 | Seeking Alpha | ||
| 24.07. | OSR Holdings Inc.: OSR Holdings Enters into Term Sheet to Acquire Woori IO, a Pioneer in Noninvasive Glucose Monitoring Technology | 98 | PR Newswire | BELLEVUE, Wash. and SEOUL, South Korea, July 24, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company advancing biomedical and... ► Artikel lesen | |
| 15.07. | OSR appoints Andreas Niethammer as Chief Medical Officer of Vaximm AG | 1 | Seeking Alpha | ||
| 15.07. | OSR Holdings appoints Andreas Niethammer as CMO of Vaximm AG | 3 | Investing.com | ||
| 15.07. | OSR Holdings Inc.: OSR Holdings Appoints Dr. Andreas Niethammer as Chief Medical Officer of Vaximm AG, an OSR Company | 92 | PR Newswire | BASEL, Switzerland and SEOUL, South Korea, July 15, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company dedicated to advancing healthcare outcomes and... ► Artikel lesen | |
| 09.07. | OSR Holdings Inc.: OSR Holdings Announces Strategic Roadmap for Tokenization Under Reg D Framework in Partnership with BCM Europe AG | 470 | PR Newswire | BELLEVUE, Wash. and ZUG, Switzerland, July 9, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company advancing biomedical and wellness innovation, today announced... ► Artikel lesen | |
| 08.07. | OSR Holdings plans $50 million security token offering in 2025 | 1 | Investing.com | ||
| 02.07. | OSR Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.06. | OSR Holdings, Inc. - S-1/A, General form for registration of securities | 1 | SEC Filings |
1 2 Weiter >>
39 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BEAM THERAPEUTICS | 16,850 | 0,00 % | Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that... ► Artikel lesen | |
| QIAGEN | 39,420 | -0,57 % | EQS-Adhoc: QIAGEN N.V.: QIAGEN N.V. kündigt die Platzierung von Wandelschuldverschreibungen mit Netto-Aktienausgleich außerhalb der Vereinigten Staaten an | EQS-Ad-hoc: QIAGEN N.V. / Schlagwort(e): Anleiheemission
QIAGEN N.V.: QIAGEN N.V. kündigt die Platzierung von Wandelschuldverschreibungen mit Netto-Aktienausgleich außerhalb der Vereinigten... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 24,400 | 0,00 % | H.C. Wainwright hebt Kursziel für Summit Therapeutics auf 50 US-Dollar an | ||
| AMYLYX PHARMACEUTICALS | 9,420 | 0,00 % | Amylyx stoppt PSP-Programm - Goldman Sachs bleibt bei Kaufempfehlung | ||
| AVIDITY BIOSCIENCES | 48,590 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,860 | 0,00 % | Recursion Pharmaceuticals, Inc. (RXRX) Expands Rare Disease Pipeline with REV102 Acquisition | ||
| 89BIO | 9,420 | 0,00 % | 89bio, Inc.: 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN FRANCISCO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the "Company" or "89bio") (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization... ► Artikel lesen | |
| ITEOS THERAPEUTICS | 10,165 | 0,00 % | iTeos Therapeutics Inc.: iTeos Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $10.047 in Cash per Share Plus a Contingent Value Right | WATERTOWN, Mass. and GOSSELIES, Belgium, July 21, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. ("iTeos") (Nasdaq: ITOS) today announced that it has entered into a definitive merger agreement... ► Artikel lesen | |
| DYNE THERAPEUTICS | 13,745 | 0,00 % | Dyne Therapeutics stock rises after Raymond James upgrade to Strong Buy | ||
| BIONTECH | 87,35 | +0,06 % | UBS stuft Biontech auf 'Neutral' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat Biontech auf "Neutral" mit einem Kursziel von 115 US-Dollar belassen. Die Wachstumsaussichten für Comirnaty seien angesichts sich weltweit... ► Artikel lesen | |
| COGNITION THERAPEUTICS | 2,470 | 0,00 % | Cognition Therapeutics, Inc.: Cognition Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement | PURCHASE, N.Y., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative... ► Artikel lesen | |
| THARIMMUNE | 6,020 | 0,00 % | Tharimmune (THUR) Tumbles 20.7% on $5-Million Share Sale | ||
| MINERALYS THERAPEUTICS | 15,220 | 0,00 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension ... | - Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of lorundrostat in over 1,000 participants with uncontrolled or resistant hypertension in a real-world... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 12,850 | 0,00 % | ARS Pharmaceuticals, Inc. - 8-K, Current Report | ||
| ARCELLX | 70,12 | 0,00 % | Arcellx, Inc. (ACLX) Reports 97% Response Rate in CAR-T Trial |
Das Unternehmen OSR HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,760 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OSR HOLDINGS INC finden Sie auf Wallstreet Online.